Biotechs Raising New Capital in Droves

Health and Healthcare

Published: April 1, 2015 11:20 am

Biotechnology has been one of the best performing sectors in the bull market. With the industry so hot, it seems like many of the smaller players are trying to bolster their balance sheets to get enough capital for their future product pipeline plans. 24/7 Wall St. has tracked several biotechs raising capital in secondary offerings this week — for what appears to be close to $550 million in total.

Celladon Corp. (NASDAQ: CLDN) filed to sell 7 million shares of its common stock. Based on the closing price of $21.67, from Monday, March 30, the offering would be valued at $151.69 million. Note that at the end of 2014, the company reported its total assets as $89.11 million. Shares of Celladon were down 2% at $18.56 Wednesday, in a 52-week trading range of $7.82 to $28.25. The company has a market cap of $426 million.

Coherus Biosciences Inc. (NASDAQ: CHRS) announced that it has priced 4.14 million shares in a secondary offering at $29.00 per share. This would value the filing at approximately $120 million. Coherus’s total assets as of the end of December were $187.22 million. Shares of Coherus fell 9.3% to $27.75. The stock has a 52-week trading range of $12.38 to $33.30, and the market cap is $926 million.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) filed to sell $150 million worth of ordinary shares. No other terms were given in the filing for pricing or number of shares. The company reported that its total assets at the end of 2014 were $32.93 million. Shares of Galmed were down 6% at $8.86, in a 52-week range of $4.58 to $13.50. The company’s market cap is $98 million.

ALSO READ: RBC’s 4 Biotech Stocks to Buy After Big Pullback

Trillium Therapeutics Inc. (NASDAQ: TRIL) announced that it will have a 2.6 million-share secondary offering. Shares priced at $19.50, valuing the total offering at $50.7 million, before taking out underwriting discounts and commissions. Shares of Trillium were up 10.5% at $22.35. The stock has a 52-week trading range of $5.64 to $22.46.

Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) announced that it will have a secondary offering of common stock valued up to $75 million. No terms were given on the pricing or the number of shares being offered. The company totaled its assets at the end of 2014 arriving at a value of $189.07 million. Shares of Raptor were down 4.3%, at $10.40 on a 52-week range of $7.12 to $12.20. The company has a market cap of $719 million.

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.